Streetbeat News

Price Targets

ITCI

RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a price target of $86. This reaffirmation of the stock's potential could influence investor sentiment and the stock's short-term performance.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 3:50 pm

RCL

Susquehanna analyst Christopher Stathoulopoulos has maintained a Positive rating on Royal Caribbean Group (NYSE:RCL) and increased the price target from $120 to $150.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 3:50 pm

NCLH

Susquehanna analyst Christopher Stathoulopoulos has maintained a Neutral rating on Norwegian Cruise Line (NYSE:NCLH) and increased the price target from $14 to $20.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 3:48 pm

CP

Susquehanna analyst Bascome Majors has maintained a Neutral rating on Canadian Pacific Kansas (NYSE:CP) but has reduced the price target from $87 to $85.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 3:43 pm

GOOGL

RBC Capital analyst Brad Erickson has reiterated an Outperform rating on Alphabet (NASDAQ:GOOGL) and maintained a price target of $155. This reaffirmation of the stock's potential could influence investor sentiment and market performance of Alphabet's shares in the short term.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 3:42 pm

CADE

RBC Capital analyst Jon Arfstrom has reiterated a 'Sector Perform' rating on Cadence Bank (NYSE:CADE) and maintained a price target of $31. This reaffirmation of the bank's rating and price target suggests that RBC Capital views Cadence Bank's stock performance as aligned with the overall sector's performance.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 3:40 pm

CTRE

RBC Capital analyst Michael Carroll has maintained an Outperform rating on CareTrust REIT (NYSE:CTRE) but has reduced the price target from $25 to $24.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 3:31 pm

MRU

RBC Capital analyst Irene Nattel has maintained a 'Sector Perform' rating on Metro, but has lowered the price target from C$83 to C$82.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 3:27 pm

CLS

RBC Capital analyst Maxim Matushansky has maintained an Outperform rating on Celestica (NYSE:CLS) and increased the price target from $33 to $38.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 3:24 pm

CP

RBC Capital analyst Walter Spracklin has maintained an Outperform rating on Canadian Pacific Kansas but has lowered the price target from C$128 to C$127.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 3:22 pm